RJA
CLBT icon

Raymond James & Associates’s Cellebrite CLBT Stock Holding History

Raymond James & Associates’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$465K Buy
+27,630
New +$410K ﹤0.01% 3158

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $315M AUM 62.95% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CC
Crosslink Capital Menlo Park, California $1.02B AUM 9.21% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.37B AUM 36.36% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Raymond James & Associates's CLBT Position: Q3 2024 in Review

Raymond James & Associates opened a new position in Cellebrite (CLBT) in Q3 2024: 27,630 shares worth $465K. The stake represents ﹤0.01% of the portfolio and ranks #3158 among its holdings.

164 funds tracked by Wall St. Rank hold CLBT as of Q3 2024.

  • Raymond James & Associates held 27,630 shares of Cellebrite worth $465K as of Q3 2024.
  • Cellebrite was a new Raymond James & Associates position in Q3 2024.
  • Cellebrite made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3158 holding.
  • 164 funds tracked by Wall St. Rank held Cellebrite as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.